Baxdrostat is a highly selective, second-generation, nonimidazole aldosterone synthase inhibitor; 100 times less baxdrostat is required for inhibition of aldosterone synthesis than for inhibition of ...

UK start-up George Medicines has brought its triple therapy for high blood pressure over the finish line, with an FDA approval that sets up a launch before the end of this year.